search icon
  • Print
  • ShareThis
  • Text Size

RSS Feed Print Category View
Gilead Passes Two Phase III Test with HCV Pill
Posted: Monday, February 4, 2013 1:37 PM

"Three down, one to go. Gilead Sciences met the main goals of two Phase III studies with its blockbuster hopeful sofosbuvir in patients with hepatitis C virus. The biopharma giant aims to use the results from the late-stage studies as part of a larger data package, which will go to the FDA later this year in the company's bid to advance the first all-oral attack on the liver-damaging disease."

To read more: Gilead passes two Phase III tests with key hep C pill - FierceBiotech


| HIVMA | Contact Us

© Copyright IDSA 2015 Infectious Diseases Society of America

Full Site Mobile Site